Injectable GHK-Cu has demonstrated systemic effects in animal models -- lung fibrosis protection, connective tissue remodeling, neuroprotection -- but translating those findings to human subcutaneous injection protocols remains speculative
Data was acquired using Thermo Xcalibur 4.0 Software (Thermo Scientific, Waltham, MA USA) MS data processing and analysis were made using Skyline software (V20, MacCoss Lab, University of Washington, Seattle, WA)
Radiometric assays for mammalian epoxide hydrolases and glutathione S-transferase
This is highly speculative because: Oral bioavailability differs between species Route of administration affects systemic exposure Species differences in peptide metabolism and clearance are unknown Current Practice Patterns Current practice patterns from unregulated sources typically involve: Subcutaneous injection: 0.25-0.5 mg once or twice daily, administered near injection sites for localized effects or abdominally for systemic distribution
Why Normal Methods Fail Single-mechanism approaches have a ceiling
Kawas served as CEO until 2021